GLP-1 therapy is bigger than weight loss.
GLP-1 receptors are expressed throughout the body: brain, heart, liver, gut. The clinical implications extend well beyond the scale.
Physician-led GLP-1 care, calibrated to your full metabolic picture.
15–20%
Average weight loss
Semaglutide/tirzepatide trial data
3–6 mo
Results timeline
Excess adiposity is a metabolic disease. The goal of treatment is metabolic normalization.
The dominant driver of excess weight is not insufficient effort. It is metabolic dysfunction. Insulin resistance, hormonal dysregulation, chronic inflammation, and the physiological adaptations that resist weight loss are well-characterized biological processes. Addressing them requires clinical intervention, not lifestyle advice alone.
The clinical consequences of adiposity extend far beyond body composition. Excess adiposity is among the strongest modifiable drivers of cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, sleep apnea, and several malignancies. Meaningful, sustained metabolic improvement changes these trajectories and, in some cases, reverses them.
GLP-1 and dual GLP-1/GIP medications represent the most clinically significant advance in metabolic medicine in decades. Trial data demonstrates cardiovascular event reduction, HbA1c normalization, and hepatic steatosis improvement. The scale is one metric. It is not the primary outcome.
A prescription alone is not a protocol.
No baseline metabolic workup
Most GLP-1 prescriptions are written without baseline HbA1c, fasting insulin, lipids, hormones, or liver function, all markers that determine candidacy, risk, and expected response.
No structured dose titration
Standard protocols often escalate dosing too quickly, increasing side effects and dropout rates. Crimson titrates gradually, adjusting based on your individual response and tolerability.
No ongoing monitoring
A prescription followed by an annual check-in isn't metabolic care. Crimson retests at 3 months to assess response and at 6 months to confirm optimization, then continues from there.
GLP-1 is not a weight loss drug. It is a metabolic and neuroendocrine signaling molecule.
GLP-1 receptors are expressed in the heart, liver, brain, immune cells, and vascular endothelium. This receptor distribution explains why GLP-1 therapy is showing clinical benefit well beyond its original indications, and the research pipeline is among the most active in all of medicine.
20% reduction in major cardiovascular events
The SELECT trial (a 17,000-patient, multi-year randomized controlled trial) demonstrated that semaglutide reduced heart attack, stroke, and cardiovascular death by 20% in patients with existing cardiovascular disease but without diabetes. This was independent of weight loss and is among the most significant cardiovascular trial results in the last decade.
GLP-1 without monitoring is
an incomplete protocol.
Most GLP-1 prescriptions are issued without a baseline metabolic workup, without structured dose titration, and without follow-up labs. Crimson tracks the markers that determine whether the drug is working, not just the weight.
Baseline labs recommended before starting: HbA1c, fasting insulin, hsCRP, lipids, hormones, liver enzymes
Retesting at 3 and 6 months: every dose decision is data-driven
Lean mass preservation monitored alongside weight reduction
Sub-therapeutic dosing for patients who aren’t seeking weight loss.
Sub-therapeutic GLP-1 dosing is an emerging area of clinical investigation. Early data suggests potential metabolic and anti-inflammatory signaling effects at doses that do not produce significant appetite suppression or weight change. This is not a standardized or FDA-approved indication, and the evidence base remains preclinical and early-phase.
This approach is not yet protocol-standardized, and Crimson evaluates candidacy on the basis of clinical and biomarker data rather than symptom self-report alone. Where the data supports it, microdosing may be incorporated into a broader longevity or optimization protocol.
Explore microdosing candidacyAnti-inflammatory
Sub-therapeutic GLP-1 signaling modulates inflammatory cytokines and hsCRP, markers of chronic, systemic inflammation that drive cardiovascular and metabolic disease risk.
Metabolic maintenance
For patients in metabolic remission or with borderline insulin resistance, microdosing may support metabolic homeostasis without the weight loss effects of standard dosing.
Neuroprotective signaling
Brain GLP-1 receptor activation is under active investigation for its role in neuroinflammation, dopamine maintenance, and amyloid clearance. Microdosing may preserve these benefits at tolerated doses.
Candidacy by biomarker
Crimson does not offer microdosing based on patient preference alone. Candidacy is determined by a full metabolic and inflammatory workup and incorporated into protocols where the data supports it.
Choose your treatment.
Both programs include monthly async physician follow-up, physician review, and structured dose titration. Flat-rate pricing covers all dose levels. Baseline labs are recommended to track metabolic progress beyond the scale and are purchased separately. Medications are prescribed when clinically indicated and billed separately.
GLP-1 · Injectable
Semaglutide
$199/mo
Billed monthly · All doses included
- Monthly async physician follow-up included
- HbA1c improvement in pre-diabetic and diabetic patients
- Cardiovascular risk reduction studied in SELECT trial
- Baseline labs recommended to track metabolic progress (separate purchase)
Medications prescribed when clinically indicated, billed separately.
Get Started →
GLP-1/GIP · Injectable
Tirzepatide
$299/mo
Billed monthly · All doses included
- Monthly async physician follow-up included
- Superior A1C, fasting insulin, and lipid improvements vs. GLP-1 alone
- Dual incretin mechanism: broader metabolic impact than GLP-1 monotherapy
- Baseline labs recommended to track metabolic progress (separate purchase)
Medications prescribed when clinically indicated, billed separately.
Get Started →All plans are HSA/FSA eligible · Cancel anytime · No hidden fees
Physician-led GLP-1 care, refined over time.
Every Crimson GLP-1 protocol follows the same evidence-based structure.
01
Baseline Labs
Comprehensive metabolic, hormonal, and cardiovascular workup recommended before starting. Purchased separately — essential for tracking progress beyond the scale.
02
Physician Review
A licensed physician reviews your labs, confirms candidacy, and builds your personalized protocol.
03
Structured Titration
Medication is delivered monthly. Dosing escalates gradually, adjusted based on your response and tolerability.
04
Retest & Act
Labs retested at 3 and 6 months. Your physician reviews every result and acts on what it shows: dose adjustment, protocol modification, or confirmation that treatment is working as intended.
Real people. Real results.
“I'd tried every diet imaginable. With Crimson's GLP-1 program, everything changed. I'm not just lighter. I'm healthier and finally free from food obsession.”
Sarah M.
GLP-1 Therapy
“The lab work caught my pre-diabetes before I had any symptoms. Six months later my A1C is in the normal range. This changed the trajectory of my health.”
David R.
GLP-1 Therapy
We work with your healthcare team, not around it.
Weight-related comorbidities (diabetes, cardiovascular disease, sleep apnea, fatty liver) often require specialist management. When your labs or clinical picture indicate that a referral is appropriate, we make it. Crimson results are shareable with your primary care physician or any specialist involved in your care.
Results shareable with your PCP
Referrals when comorbidities require specialist care
Clinical documentation for any provider
Coordination, not replacement
Frequently asked
questions
GLP-1 therapy is one of the most powerful tools in preventive medicine. Use it correctly.
Start with labs. Confirm candidacy. Build the right protocol.
Get Started